|
La Jolla Pharmaceutical Company's
proprietary Tolerance Technology®
platform has been developed by the Company
to address the underlying causes of
life-threatening antibody-mediated diseases.
Using this platform, the Company is
focused on the discovery and development
of novel therapeutics, called Toleragens,
designed to suppress the production
of specific disease-causing antibodies
without affecting the protective functions
of the immune system.
Toleragens are therapeutic molecules that consist of a carrier
platform that serves as a vehicle for presenting epitopes that
are recognized by antibody receptors on the targeted B cell.
Based on well-accepted findings from the scientific literature,
when an epitope binds and cross-links the antibody receptors on
the B cell in the absence of a T cell signal, the B cell becomes
anergic (unresponsive) or becomes tolerized and undergoes a natural
form of cell death called apoptosis. In either case, the B cell
ceases to produce antibodies.
To date, the Company has developed Toleragens with epitopes
made from oligonucleotides (DNA), peptides, and carbohydrates.
LJP has shown in animal models of lupus, antibody-mediated thrombosis
and xenotransplantation that each kind of Toleragen is able to
reduce production of the targeted antibodies and the B cells producing
them. Based on these studies, LJP believes it can create Toleragens
for a number of diseases.
Currently, we own 101 issued patents and have 84 pending patent
applications covering our various technologies and drug candidates,
including our Tolerance Technology, our lupus and antibody-mediated
thrombosis drug candidates, and our carrier platform and linkage
technologies for our Toleragens.
Terms
of Use & Privacy Policy
Copyright © 2007, La Jolla Pharmaceutical
Company
|